From the Division of Nutritional Sciences, Cornell University, Ithaca, New York 14853
Received for publication, January 2, 2001, and in revised form, March 8, 2001
![]() |
ABSTRACT |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We have elucidated a biochemical mechanism
whereby changes in iron metabolism cause changes in
folate-dependent one-carbon metabolism. Although animal and
clinical studies have demonstrated that perturbations in iron status
and metabolism alter folate metabolism, the biochemical mechanisms
underlying these associations have yet to be identified. The effect of
altered ferritin expression on folate metabolism was determined in
human MCF-7 cells and SH-SY5Y neuroblastoma. Cells expressing rat heavy
chain ferritin (HCF) exhibited markedly increased expression of the
folate-dependent enzyme cytoplasmic serine
hydroxymethyltransferase (cSHMT). These effects were not seen when rat
light chain ferritin was expressed. Additionally, cSHMT expression was
not altered when HCF expression was induced in MCF-7 cells cultured
with supplemental ferric citrate. This indicates that cSHMT expression
is increased by elevated HCF concentrations, independent of increased
iron availability, suggesting that cSHMT expression may respond to
HCF-induced chelation of the regulatory iron pool. Increased HCF
expression did not alter cSHMT mRNA levels, but did increase
translation rates of cSHMT mRNA. The increase in translation was
mediated, at least in part, through the cSHMT 5'-untranslated region of
the transcript. MCF-7 cells with increased expression of cSHMT
displayed increased efficiency of de novo thymidylate
biosynthesis, indicating that thymidylate synthesis is normally limited
by cSHMT activity in MCF-7 cells. Our data suggest that the iron
regulatory pool may play an important role in regulating folate
metabolism and thereby thymidine biosynthesis.
The influence of iron deficiency, both induced and naturally
occurring, on folate metabolism has been well documented in cell culture models, animal models, and humans. Iron deficiency can influence folate status, modify folate metabolism, and result in
hematological pathologies similar to those normally attributed to
folate deficiency (1). It is not certain if all observed effects of
iron deficiency on folate status reflect actual changes in
intracellular folate concentrations or are due to alterations in
folate-dependent metabolism. Studies of iron-deficient rats have demonstrated a 90% decrease in serum folate levels compared with
their iron-sufficient controls (2). The decreased serum folate is not
secondary to intestinal malabsorption, changes in intestinal flora,
isolated folate malabsorption, or changes in vitamin
B12 status. In addition, maternal iron deficiency in rats decreases the secretion of folate into milk (3-6), sacrificing folate
metabolism in the pups while maintaining maternal serum and red blood
cell folate levels. Many of the findings in rats have been replicated
in other mammals and in pregnant and non-pregnant humans (2, 7, 8). In
humans, iron deficiency impairs folate utilization in certain tissues,
decreases polyglutamation levels of folate, decreases the secretion of
folate into breast milk without decreasing maternal folate stores, and
can cause granulocyte abnormalities characteristic of folate
deficiencies (1, 4, 9-12). Despite the numerous clinical associations, the biochemical mechanisms underlying the influence of iron deficiency on folate metabolism have not been established (3-6, 11, 13).
The regulation of iron status and intracellular iron concentrations is
complex. Cellular iron can be categorized into three pools: the
functional, storage, and regulatory pools (14). The functional iron
pool refers to the iron incorporated into proteins that require the
mineral for enzymatic function or structural integrity, including
hemoglobin and ribonucleotide reductase. The storage iron pool refers
to iron that is associated with the iron storage protein ferritin (14).
Finally, the regulatory iron pool is the iron that is in equilibrium
with the iron regulatory proteins
(IRPs).1 It is this pool of
iron that is therefore critical for the translational regulation of
mRNA species that contain iron regulatory elements, including
ferritin and transferrin receptor transcripts (15). When the regulatory
iron pool is decreased, IRPs bind to these mRNA elements and
inhibit specific mRNA translation or degradation (15).
In the cell, iron is an effective and deleterious oxidizing agent. The
cell prevents iron-mediated oxidative damage by chelating and storing
intracellular iron within the protein complex that is ferritin.
Ferritin is a heterogeneous protein composed of heavy chain (HCF) and
light chain (LCF) subunits (16). In mammals, HCF and LCF share 54%
sequence identity and assemble in varying proportions to make up a
complex of 24 subunits (14). The ratio of heavy to light isomers varies
depending on cell type and function (17). The heavy chain isomer has
the capacity to sequester iron through its ferroxidase active sites,
whereas LCF is believed to function in mineralizing iron at the core of
the ferritin polymer (18). Increased HCF expression can be induced in
cell culture models, resulting in chelation and subsequent lowering of
the regulatory iron pool (19), whereas elevations in LCF levels in vivo have no effect on the regulatory iron pool (20).
Current literature indicates that changes in the ferritin subunit ratio generally result from transcriptional regulation of the gene encoding HCF. Hormones and other factors, including c-Myc, estrogen, and pro-inflammatory cytokines during infections, can specifically increase HCF transcription (21-23).
Sequestration of intracellular iron from all iron pools can be
achieved using chemical iron chelators such as deferoxamine and
mimosine. These chelators have been shown to reduce iron incorporation into ferritin (24). Recently, we found that chemical chelators can
alter folate metabolism in a tissue-specific manner by modifying the
expression of the folate-dependent enzyme cytoplasmic
serine hydroxymethyltransferase (cSHMT) (25). We demonstrated that iron
sequestration may play a regulatory role in folate metabolism by
inhibiting cSHMT transcription. The effect of iron chelators on cSHMT
transcription appears to be novel and unrelated to known mechanisms
through which iron regulates gene expression (25).
The SHMT enzyme catalyzes the tetrahydrofolate
(THF)-dependent interconversion of glycine and serine
(Scheme 1). This reaction is the primary
source of folate-activated one-carbon units. There are three
biosynthetic pathways that are associated with cytoplasmic folate
metabolism and that require folate-activated one-carbon units: purine
biosynthesis, which requires the 10-formyl-THF cofactor; thymidine
biosynthesis, which requires 5,10-methylene-THF; and methionine
synthesis (homocysteine remethylation), which requires 5-methyl-THF
(26). There are two intracellular isoforms of SHMT, one located in the
mitochondria and the other in the cytoplasm. Mutagenesis studies have
demonstrated that the mitochondrial isozyme is essential for the
generation of glycine and presumably formate (Scheme 1). Chinese
hamster ovary cells lacking mitochondrial SHMT activity are auxotrophic
for glycine (27), suggesting that cSHMT activity cannot replace
mitochondrial SHMT function. The inability of cSHMT to compensate for
the loss of mitochondrial SHMT function indicates that the cSHMT
isozyme is not a primary source of glycine and perhaps one-carbon
units. The SHMT-catalyzed reaction is freely reversible in
vitro using physiological concentrations of amino acid and folate
substrates (28, 29). Therefore, the enzyme, when catalyzing serine
degradation, can supply 5,10-methylene-THF for biosynthetic reactions;
and when catalyzing serine synthesis, it can deplete 5,10-methylene-THF
pools and regenerate THF for purine biosynthesis. Consequently, cSHMT
is poised to regulate the supply of folate-activated one-carbon units
for both DNA synthesis and methionine regeneration.
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
View larger version (11K):
[in a new window]
Scheme 1.
Overview of folate metabolism.
Folate metabolism is required for the synthesis of purines,
thymidylate, and methionine in the cytoplasm. Sources of the one-carbon
units for cytoplasmic folate metabolism include mitochondrially derived
formate or serine through the action of cytoplasmic serine
hydroxymethyltransferase.
The ability of iron chelators to influence cSHMT expression may begin
to provide a mechanistic rationale for the known associations between
iron and folate metabolism. The cSHMT enzyme is potentially critical
for regulating folate metabolism because of its capacity to regulate
the flux of folate substrates, and cSHMT is known to be sensitive to
extreme alterations in intracellular iron concentrations as those
induced by chemical chelators (25). However, the use of chemical iron
chelators to mimic iron deficiency is not an adequate model to test the
physiological relevance of cSHMT regulation by iron. Therefore, in this
study, we examined the ability of the endogenous iron chelator HCF to
influence cSHMT expression and activity in cell culture models.
![]() |
EXPERIMENTAL PROCEDURES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Cell Lines and Media--
Human MCF-7 mammary adenocarcinoma
cells (ATCC HTB22) and SH-SY5Y neuroblastoma, a subline of the SK-N-SH
neuroblastoma, have been previously described (28). Cells were cultured
with -minimal essential medium (
-MEM; Hyclone Laboratories)
supplemented with 11% fetal calf serum (Hyclone Laboratories) and
maintained at 37 °C in a 5% CO2 atmosphere.
Generation of Rat HCF- and LCF-expressing Cell Lines--
MCF-7
cells were cultured in 100-mm culture dishes with -MEM and grown to
80% confluency. The cells were harvested by trypsinization and washed
with phosphate-buffered saline, and 1 × 107 cells
were incubated on ice for 10 min before 10 µg of plasmid DNA was
added. The cells were electroporated at 0.22 kV and 950 microfarads
(using a Bio-Rad Gene-Pulser). Cells were cultured with
-MEM for
48 h and then cultured with G418 sulfate (500 µg/ml)-supplemented
-MEM to select for stable integrants. The
plasmid (pcDNA3 vector, Invitrogen) contained the open reading
frame cDNA for either rat HCF or LCF (30). Over 10 colonies were
isolated and passaged until stable lines were generated.
Generation of Antisense cSHMT-expressing Cell Lines-- The antisense cSHMT construct was generated by transcriptase-polymerase chain reaction (RT-PCR). Total mRNA was isolated from MCF-7 cells (PurgeneTM RNA isolation kit) and converted to cDNA using Tth polymerase (Promega) and random hexamer primers. The first 405 base pairs (bp) of the human cSHMT cDNA were amplified using forward primer 5'-TTCATGAATTCGGGTCAGCGGGTCTGGGACTGGTGG-3' and reverse primer 5'-ACTAAGGATCCTCAAATCACTGTCTTTGAGGG-3'. The forward primer contains an EcoRI restriction site at the 5'-end, whereas the reverse primer contains a BamHI restriction site. The cycling conditions were 94 °C for 45 s, 55 °C for 45 s, and 70 °C for 90 s for a total of 30 cycles. The PCR product was digested with EcoRI and BamHI and subcloned into the pcDNA3 vector described above. The sequence was verified by nucleotide sequencing. Once verified, the construct was transfected into MCF-7 cells. Stable cell lines expressing the antisense construct were also generated by the procedure described above.
Western Blot Analyses-- Cells were harvested by trypsinization and washed with phosphate-buffered saline. Cell pellets were incubated at 100 °C for 10 min in buffer containing 2% SDS, 100 mM dithiothreitol, and 60 mM Tris (pH 6.8). Cellular proteins (40-120 µg) were separated by SDS-polyacrylamide gel electrophoresis (PAGE) using 10-12% polyacrylamide gels. Proteins were transferred at 4 °C to a polyvinylidene fluoride microporous membrane (Millipore Corp.) using a Transblot apparatus (Bio-Rad). Following transfer, membranes were incubated with primary antiserum for 15 h at 4 °C, washed with phosphate-buffered saline and 0.1% Tween 20, and then incubated for 4-15 h with the appropriate horseradish peroxidase-conjugated secondary antibody. Rat ferritin (Sigma) was used as a standard for all ferritin Western blot analyses, and recombinant human cSHMT was used as a standard for cSHMT Western blot analyses. The membranes were visualized using the horseradish peroxidase SuperSignal chemiluminescent substrate system (Pierce).
For detection of HCF, sheep anti-human HCF antiserum (30) was diluted 1:8000, and the secondary antibody (rabbit anti-sheep IgG, Pierce) was diluted 1:6500. For LCF detection, rabbit anti-rat LCF antiserum (30) was diluted 1:8000, and the secondary antibody (anti-rabbit IgG, Pierce) was diluted 1:5000. For thymidylate synthase detection, monoclonal mouse anti-human thymidylate synthase antiserum (NeoMarkers) was diluted 1:1000, and the anti-mouse goat IgG secondary antibody was diluted 1:3500. For cSHMT detection, sheep anti-human cSHMT antiserum (31) was diluted 1:7500, and rabbit anti-sheep IgG antiserum was diluted 1:6500.
Ferric Citrate Supplementation--
Cells were grown for 24 h in medium enriched with 0, 0.1, 1, or 10 µM ferric
citrate. Two replicate plates were grown at each supplementation
concentration. Cells were harvested using trypsin/EDTA, washed three
times with phosphate-buffered saline, and stored at 80 °C until
Western blot analyses were conducted.
Determination of SHMT mRNA Levels by RT-PCR--
Total
cellular RNA was isolated from cells using RNAzolTM
(Teltest, Inc.) and converted to cDNA using a first strand
synthesis kit (CLONTECH). A competitive RT-PCR
method based on the MIMIC strategy (CLONTECH) was
used to measure cSHMT mRNA levels. A competitive internal standard
with the same primer-binding sites used to amplify the 300-bp segment
of the cSHMT cDNA was generated by amplifying 500 bp of
v-erbB using two composite primers (40-mers),
5'-GAACACTGCCATGTGGTGACCCGCAAGTGAAATCTCCTCCG-3' and
5'-CTTCAGTGCCACAGCAACCAAGTTGAGTCCATGGGGAGCTTT-3'. The first 20 nucleotides of the 40-mer are complementary to cSHMT, whereas the
following 20 nucleotides are complementary to v-erbB. The 540-bp internal standard was synthesized and purified following protocols described by the manufacturer. The primers used to amplify cSHMT cDNA and the internal standard were
5'-GAACACTGCCATGTGGTGACC-3' and 5'-CTTCAGTGCCACAGCAACC-3'. The
primer-binding sites are located in cSHMT exons 8 and 9, thereby
avoiding possible genomic DNA contamination. The primers used to create
the glyceraldehyde-3-phosphate dehydrogenase standard were
5'-ACCACAGTCCATGCCATCACCGCAAGTGAAATCTCCTCCG-3' and
5'-TCCACCACCCTGTTGCTGTATTGAGTCCATGGGGAGCTTT-3', and the primers used to
amplify glyceraldehyde-3-phosphate dehydrogenase were 5'-TCCACCACCCTGTTGCTGTA-3' and 5'-ACCACAGTCCATGCCATCAC-3'. To perform
the RT-PCR, 2 µg of total RNA was converted to cDNA, and the
v-erbB internal standard was added at several concentrations varying by 2-fold over the range until a target/standard ratio of 1.0 was achieved (1 × 103 to 1 × 10
7 amol/reaction). Target cDNA and the
internal standard were amplified with Taq polymerase. The
cycling parameters were 94 °C for 45 s, 65 °C for 45 s,
and 72 °C for 60 s for 28 cycles. Internal standard and target
DNA fragments were then separated on a 1.8% agarose gel and stained
with ethidium bromide solutions. DNA concentrations and cSHMT message
copy number were quantified using a ChemiImager 4400 with AlphaEase
Version 4.0 (Alpha Innotech Corp.).
Luciferase Reporter Gene Assays-- As described previously, both the full-length and shorter alternatively spliced form of the cSHMT 5'-untranslated region (UTR) were cloned into the pGL3-luciferase promoter vector (Promega) such that the cSHMT 5'-UTR was fused to the luciferase open reading frame just as it is normally fused to the cSHMT open reading frame (31, 32). The LUTR-luc (where LUTR is the long 332-bp UTR and luc is luciferase) construct encodes the full-length cSHMT UTR fused to the luciferase open reading frame, whereas the SUTR-luc (where SUTR is the short 193-bp UTR) construct encodes the shorter alternatively spliced cSHMT 5'-UTR fused to the luciferase open reading frame. The constructs were transfected with a control construct for transfection efficiency (pRL-CMV vector, Promega) into MCF-7 and rat HCF-expressing MCF-7 cells. The transfection method has been described previously (25). 48 h following transfection, the cells were assayed for luciferase activity. The activity generated from all constructs was normalized to that generated from the co-reporter pRL-CMV-Renilla luciferase. The luciferase activities generated from the LUTR-luc and SUTR-luc constructs were normalized to luciferase activity generated from the same construct lacking the cSHMT 5'-UTR in the same cell lines to control for differences in basal translation rates among cell lines. All reported luciferase activity values represent the mean of at least five measurements, and the error bars represent the S.E. values.
In Vitro Translation Assays-- RNAs corresponding to luciferase mRNA, luciferase mRNA with the cSHMT 5'-UTR fusion (Lluc-mRNA), and luciferase mRNA with the shortened alternatively spliced cSHMT 5'-UTR fusion (Sluc-mRNA) were generated using the Ribomax large-scale RNA production system/T7 kit (Promega) as described previously (32). The crude mRNA was treated with DNase I for 15 min at 37 °C and precipitated overnight in 2 M LiCl at 4 °C. All RNA procedures were conducted under RNase-free conditions, and purity was verified by electrophoresis. The translation reaction mixture containing rabbit reticulocyte lysate, 1 mM MgOAc, 2 mM dithiothreitol, and 35 mM KCl (Flexi rabbit reticulocyte lysate system kit, Promega) was incubated at 37 °C for 35 min with luciferase mRNA, Lluc-mRNA, or Sluc-mRNA templates. All experiments were performed at a final mRNA concentration of 0.2 µg/ml to ensure that the catalytic system was below saturation. The mRNA templates were heated to 65 °C for 10 min and then cooled to room temperature before addition to the reaction mixture to allow for a more uniform secondary structure to form. All enzyme/mRNA incubations contained RNase inhibitor (Ambion Inc.). To determine the effects of rat ferritin and ferric citrate on cSHMT translation, varying concentrations of rat ferritin or ferric ammonium citrate were added to the reaction mixture. Following a 35-min incubation at 30 °C, the translation reaction mixtures were quenched on ice, and the luciferase activity was determined.
Modified Deoxyuridine Suppression Assays--
Cells were plated
to a confluence of 1 × 106 cells/24-mm well and
cultured overnight with -MEM. The medium was changed to 3 ml of
defined medium, which lacked ribonucleosides, deoxyribonucleosides, thymidine, hypoxanthine, serine, and glycine. After 48 h, the medium was refreshed, and deoxyuridine was added to a final
concentration of 50 µM in experimental samples, but was
excluded from control wells. After a 90-min incubation, 5 µl of
[3H]thymidine (1 mCi/ml; PerkinElmer Life Sciences) was
added to all wells. After a 24-h incubation, cells were harvested, and DNA was isolated (PurgeneTM DNA purification kit).
Once isolated and rehydrated, DNA concentrations were determined at
A260. DNA solutions were transferred to
scintillation tubes, and [3H]thymidine incorporation into
DNA was determined using a scintillation counter to determine cpm/µg
of DNA. Data are expressed as cpm/µg of DNA in control samples
(lacking deoxyuridine) divided by cpm/µg of DNA in experimental
samples (supplemented with deoxyuridine).
![]() |
RESULTS |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Effects of Ferritin on Intracellular cSHMT
Concentrations--
Iron chelators including mimosine (33, 34) and
deferoxamine inhibit cSHMT transcription in MCF-7 cells (25), and the cSHMT protein is not detectable in cell extracts following 24 h of
exposure to these chelators. The effect of iron chelation on cSHMT
expression is cell-specific; cSHMT protein levels are not affected by
iron chelators in human SH-SY5Y neuroblastoma. To determine if cSHMT
expression was responsive to changes in the cellular iron regulatory
pool, the effects of rat HCF and LCF expression on cellular cSHMT
protein concentrations were determined in MCF-7 and SH-SY5Y cells.
Others have shown that increased expression of HCF, but not LCF, in
mammalian cells decreases the cellular concentration of free
non-ferritin bound iron (19, 35). In our study, both MCF-7 and SH-SY5Y
cells were transfected with a plasmid that expresses either rat HCF or
LCF cDNA, and stable clones were isolated. Clonal lines were
screened for changes in HCF, LCF, and cSHMT protein levels (Figs.
1 and 2).
|
Fig. 1 shows the effects of expressing rat HCF cDNA on cSHMT
protein levels in SH-SY5Y neuroblastoma (A) and MCF-7 cells
(B) as determined by Western blotting. The upper
panels verify that HCF protein levels were increased in both
G418-resistant MCF-7 and SH-SY5Y cell lines. Surprisingly, we found
that cSHMT protein levels were also elevated 5-10-fold in all
HCF-expressing MCF-7 cell lines, indicating that increased rat HCF
expression has the opposite effect of chemical chelators on cSHMT
protein concentrations. This effect on cSHMT protein concentrations was
also seen in all SH-SY5Y clonal cell lines. This indicates that, unlike
the effects of iron chelators on cSHMT expression (25), the effects of
HCF are not cell-specific for MCF-7 cells since both cell lines had increased cSHMT protein levels when rat HCF was expressed. As a control
experiment, stable MCF-7 cell lines that express rat LCF were generated
(Fig. 2A). The MCF-LCF5 clonal
line displayed the highest level of LCF expression, although increased
LCF expression was seen in all G418-resistant cell lines upon longer
exposure of the blots. These cells would not be expected to display
changes in the iron regulatory pool, as the LCF subunit lacks the
ferroxidase activity necessary for significant iron uptake by ferritin.
As expected, MCF-7 cell lines expressing rat LCF did not display alterations in cSHMT concentrations (Fig. 2B). Collectively,
these data indicate that cSHMT protein levels are increased either
directly by increased HCF protein or indirectly by responding to
HCF-induced changes in the iron regulatory pool.
|
Effect of Exogenous Iron on cSHMT Expression--
The regulatory
iron pool is sensitive to and typically reflective of exogenous iron
concentrations. In cell culture models, it has been demonstrated that
increasing iron in the culture medium results in increased ferritin
synthesis and decreased synthesis of transferrin receptors (36). IRPs
sense and respond to changes in the iron regulatory pool by altering
the translation of ferritin mRNA and increasing the stability of
the transferrin receptor mRNA (36). The ultimate role of IRPs is to
maintain iron homeostasis irrespective of alterations in exogenous iron
concentrations. The effects of increasing the iron regulatory pool on
cSHMT expression were determined in MCF-7 cells (Fig.
3). Increasing the concentration of
ferric citrate in the culture medium increased HCF protein levels as
expected (Fig. 3, lower panel). However, the increase in HCF
protein did not influence cSHMT protein levels. This indicates that the
mechanisms that are utilized to increase ferritin expression as a
function of iron do not influence cSHMT expression, which does not
respond to increases in the iron regulatory pool or to iron overload.
These data suggest that cSHMT protein expression, if responsive to
changes in the iron regulatory pool, is influenced only by decreases in
the iron regulatory pool under our culture conditions.
|
Effect of HCF Expression on cSHMT mRNA-- Competitive RT-PCR assays were conducted to determine the molecular mechanisms whereby HCF alters cSHMT expression. The cellular cSHMT mRNA content was determined by co-amplification of the cSHMT cDNA and an internal control cDNA containing primer-binding sites identical to those of cSHMT. The cSHMT transcript levels were quantified in both wild-type MCF-7 and SH-SY5Y cells and compared with cells lines expressing rat HCF. No significant differences in cSHMT transcript levels were found between wild-type and HCF-expressing cell lines. The average concentration of the cSHMT transcript in both MCF-7 and SH-SY5Y cells was 0.0036 amol/µg of total RNA. These data indicate that increased HCF levels do not elevate cSHMT protein levels by increasing cSHMT mRNA concentrations.
Effect of HCF on cSHMT Translation-- Expression of rat HCF in human cell cultures did not increase cSHMT mRNA as determined by quantitative RT-PCR, nor did it increase rates of cSHMT promoter activity as determined by gene reporter assays (data not shown). This indicates that ferritin increases either cSHMT translation rates or cSHMT protein stability. Table I shows evidence that ferritin increased the translation rate of the cSHMT message and that this effect was mediated through the cSHMT 5'-UTR. As a result of alternative splicing, cSHMT transcripts contained either a long 332-bp UTR or a short 193-bp UTR. 5'-UTR sequences are often binding sites for proteins that regulate rates of translation (37-40). To determine if HCF-induced increases in cSHMT protein are mediated through the cSHMT 5'-UTR, luciferase reporter gene assays were performed. Two cDNA constructs (Lluc and Sluc) that contain the cSHMT 5'-UTRs fused to the 5'-end of the luciferase cDNA (32) were transiently transfected into MCF-7 cells. The addition of the cSHMT 5'-UTR to the luciferase cDNA increased luciferase activity by 2-3-fold relative to activity generated from the luciferase cDNA alone (data not shown) when transfected into MCF-7 cells. Interestingly, this effect was even more pronounced in cells expressing the HCF cDNA. HCF-expressing cells have enhanced luciferase activity relative to control cells resulting from the presence of the 5'-UTR (41). These data demonstrate that increased HCF expression increases translation of a reporter gene containing the cSHMT 5'-UTR. It is not clear if HCF is interacting directly with the cSHMT 5'-UTR, or if it is influencing the activity of other mRNA-binding proteins that may be sensitive to decreased intracellular iron concentrations.
|
Ferritin is a promiscuous mRNA-binding protein and has been demonstrated either to activate or to inhibit in vitro translation of a variety of unrelated mRNA species (42). To determine if ferritin directly interacts with the cSHMT 5'-UTR and enhances translation in vitro, the effect of ferritin protein on the translation efficiency of Lluc-mRNA templates was determined. The addition of commercial rat ferritin (50-150 pmol) to an in vitro translation reaction decreased translation of the Lluc template by >90% at all ferritin concentrations relative to reactions that lacked ferritin. The addition of ferric citrate at concentrations ranging from 0.1 to 100 µM had no effect on the in vitro translation reaction. Therefore, it is unlikely that the HCF protein acts independently or directly on cSHMT mRNA in vivo to increase cSHMT translation. It is more probable that the HCF-induced increases in cSHMT expression are a consequence of alterations in the iron regulatory pool.
Effects of Increased cSHMT Expression on Folate
Metabolism--
The induction of cSHMT protein concentrations by HCF
suggests a mechanism whereby iron metabolism influences folate
metabolism. However, changes in cSHMT protein levels may not
necessarily result in increased cSHMT specific activity in the cell. It
has been demonstrated, for example, that the cSHMT enzyme is capable of synthesizing its own slow, tight-binding inhibitor, 5-formyl-THF. Studies in human neuroblasts indicate that cSHMT enzyme activity is
inhibited by 5-formyl-THF in these cells (28). Therefore, the effects
of altered cSHMT protein levels on cSHMT specific activity were
determined using an in vivo deoxyuridine suppression assay.
This competition assay measures the efficiency of de novo thymidylate biosynthesis (Scheme 2). The
effects of altered cSHMT activity on thymidine biosynthesis have never
been determined. The cSHMT reaction is freely reversible in
vitro at physiological concentrations of substrates and products,
indicating that cSHMT, when catalyzing serine catabolism, is capable of
providing one-carbon units in the form of methylene-THF for thymidylate
biosynthesis. Alternatively, when catalyzing serine synthesis, cSHMT
may deplete methylene-THF levels and thereby inhibit thymidylate
biosynthesis. To validate that the dUrd suppression assay is sensitive
to changes in the specific activity of cSHMT, MCF-7 cells expressing
sense and antisense cSHMT constructs were also assayed. The cell lines that express the cSHMT cDNA contained 2-4-fold increased cSHMT protein levels, and the antisense cSHMT cells contained ~80%
decreased cSHMT protein compared with MCF-7 cells (data not shown).
Therefore, the effects of altered cSHMT protein levels (due to
overexpression of the human cSHMT cDNA, to expression of an
antisense construct, or to overexpression of HCF) on de novo
thymidylate biosynthesis were determined (Scheme 2 and Table
II). The data demonstrate that increased
cSHMT protein levels increase relative dUrd suppression values, whereas
expression of the antisense construct decreases relative dUrd
suppression values. An increased dUrd suppression value indicates that
less exogenous [3H]dTTP was incorporated into cellular
DNA during the assay, indicating more efficient de novo
thymidylate biosynthesis. As a control experiment, the effects of HCF
expression on thymidylate synthase protein levels were determined. Fig.
4 demonstrates that although thymidylate
synthase protein levels varied modestly among cell lines, there was no
correlation between thymidylate synthase protein levels and dUrd
suppression values. These data demonstrate that elevated cSHMT activity
enhances de novo thymidine biosynthesis, presumably by
increasing methylene-THF availability for thymidylate synthase by
increasing serine catabolism (Schemes 1 and 2), and indicate that
de novo dTMP synthesis is limited by cSHMT activity in
MCF-7 cells.
|
|
|
Effects of cSHMT Expression on Genome-wide Protein Expression in
MCF-7 Cells--
In the course of generating cell lines with altered
cSHMT expression, it was observed that increases in cSHMT enzyme levels are associated with alterations in the SDS-PAGE profile generated from
total MCF-7 cellular protein extracts. As shown in Fig.
5, Coomassie Blue-stained
SDS-polyacrylamide gels of crude cell extracts demonstrated that MCF-7
cells expressing the sense cSHMT construct or the rat HCF construct
have similar protein profiles, but differ from wild-type MCF-7 cellular
protein profiles. The bands that displayed the greatest changes in
intensity were not the cSHMT protein, which is a 55-kDa protein.
Additionally, the changes were identical in all clonal cell lines that
express a sense cSHMT construct or an HCF construct. The profile
changes observed with increased cSHMT expression were not observed when
the antisense cSHMT construct was expressed. This suggests that
increases in cSHMT protein levels alter the expression of other genes
in MCF-7 cells. Therefore, either increased cSHMT protein directly
influences the expression of other genes, or cSHMT-induced
perturbations in folate metabolism modulate the expression of other
genes.
|
![]() |
DISCUSSION |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Our previous studies have demonstrated that chemical chelators inhibit cSHMT expression at the transcriptional level in a cell-specific manner (25). Our findings here, however, demonstrate that iron chelation by HCF induces cSHMT expression at the translational level. This latter alteration in cSHMT expression appears to be unrelated to the transcriptional effects induced by chemical iron chelators. This notion is supported by our studies demonstrating that chemical chelators act on cSHMT expression in a cell-specific fashion, whereas the effect of HCF on cSHMT expression may represent a more global mechanism. Therefore, chemical iron chelation and HCF-mediated iron chelation likely affect cSHMT expression by distinct mechanisms. Chemical iron chelators can sequester both the regulatory and functional iron pools, whereas HCF expression can influence only the regulatory iron pool. The HCF induction of cSHMT expression is likely due to changes in the iron regulatory pool, whereas chemical iron chelators may act by disrupting a cell-specific iron-binding protein that is important in cSHMT transcriptional regulation. We also conclude that HCF-induced increases in cSHMT expression do not occur by the same mechanisms that regulate ferritin and transferrin synthesis (i.e. mediation by IRPs) since cSHMT protein levels do not respond to elevations of iron in the culture medium. The data indicate that cSHMT expression responds only to decreases in the regulatory iron pool, and the effects of iron chelation on cSHMT expression are distinct depending on the primary catalyst for iron depletion.
This study demonstrates a complex relationship between cellular iron status and folate metabolism and suggests that changes in cSHMT translation may be responsible for mediating the metabolic associations between iron and folate metabolism. The cSHMT enzyme catalyzes the interconversion of glycine and serine and is functionally poised to regulate the flux of one-carbon units to the different folate-dependent biosynthetic pathways in the cytoplasm by manipulating 5,10-methylene-THF pools. Our results indicate that increases in cSHMT activity cause changes in the flux of one-carbon units through the thymidylate biosynthetic pathway and that cSHMT activity is limiting in thymidylate biosynthesis in MCF-7 cells. It is well established that impaired folate metabolism results in increased uracil content in DNA resulting from impaired thymidylate synthesis (43, 44). Increased DNA uracil content is associated with several cancers (45), and impaired de novo thymidylate biosynthesis has been implicated in the etiology of neural tube defects in Pax3 mice (46). Our studies indicate that the specific activity of cSHMT potentially influences the uracil content in DNA. In addition, increases in cSHMT-catalyzed serine synthesis may decrease 5-methyl-THF availability and therefore impair homocysteine remethylation as demonstrated in cell culture systems (28). It is therefore possible that iron-mediated increases in cSHMT activity could be implicated in the development or prevention of certain clinical disorders by impairing homocysteine remethylation and enhancing dTMP synthesis.
Our data suggest that cSHMT is a key regulatory enzyme in folate metabolism. cSHMT displays robust changes in expression resulting from changes in iron status and metabolism (25) as well as from retinoic acid exposure (47). Therefore, cSHMT may be a homeostatic sensor that effects changes in folate metabolism when signaled by seemingly unrelated metabolic pathways. Additionally, these changes in cSHMT expression alter the expression of several proteins in MCF-7 cells, possibly due to changes in one-carbon metabolism, e.g. these genes may be methylation-sensitive. Alternatively, we recently demonstrated that cSHMT is an mRNA-binding protein (32). cSHMT may therefore influence alterations in protein expressions by directly modifying the translation of some mRNA species.
The results of this study provide evidence for a general mechanism
whereby alterations in iron metabolism can affect changes in
folate-mediated one-carbon metabolism. We propose that this mechanism
is triggered by decreases in the regulatory non-ferritin bound iron
pool. Several studies have demonstrated that HCF functions intracellularly to sequester iron into ferritin, whereas LCF is believed to function in the mineralization of iron at the core of
ferritin. Increased expression of HCF in cell culture models lowers the
free iron regulatory pool (19, 35). Physiologically, HCF (but not LCF)
levels are increased in tissues >10-fold during pregnancy and cancer
and as a result of ethanol exposure (48-50). These physiological
states are also associated with altered folate metabolism (51-53);
however, the specific mechanisms underlying these alterations have not
been characterized. In addition, there are direct associations in the
literature between iron deficiency and aberrations in folate
metabolism. Here, we show that both human neuroblastoma and MCF-7 cells
have increased cSHMT protein levels only when the HCF (but not LCF)
protein is increased. In addition, we found that increased cSHMT
modulates the flux of one-carbon units available for the
folate-dependent biosynthetic reaction of thymidylate
synthesis. The results of this study therefore reveal a physiological
mechanism that may explain the parallels and associations between iron
and folate metabolism.
![]() |
FOOTNOTES |
---|
* This work was supported in part by United States Public Health Service Grants HD35678 and DK49621 (to P. J. S.) and Training Grant DK07158-21 (to E. W. O.).
To whom correspondence should be addressed. Tel.:
607-255-9751; Fax: 607-255-9751; E-mail: pjs13@cornell.edu.
Published, JBC Papers in Press, March 12, 2001, DOI 10.1074/jbc.M100039200
![]() |
ABBREVIATIONS |
---|
The abbreviations used are:
IRPs, iron
regulatory proteins;
HCF, heavy chain ferritin;
LCF, light chain
ferritin;
cSHMT, cytoplasmic serine hydroxymethyltransferase;
THF, tetrahydrofolate;
-MEM,
-minimal essential medium;
RT-PCR, reverse transcriptase-polymerase chain reaction;
bp, base pair(s);
PAGE, polyacrylamide gel electrophoresis;
UTR, untranslated
region.
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Westerman, D., Evans, D., and Metz, J. (1999) Br. J. Haematol. 107, 512-515[Medline] [Order article via Infotrieve] |
2. | Toskes, P., Smith, G., Giannella, R., Bensinger, T., and Conrad, M. (1972) Gastroenterology 62, 861 |
3. | O'Connor, D., Picciano, M., Tamura, T., and Shane, B. (1990) J. Nutr. 120, 499-506[Medline] [Order article via Infotrieve] |
4. | O'Connor, D., Picciano, M., Sherman, A., and Burgert, S. (1987) J. Nutr. 117, 1715-1720[Medline] [Order article via Infotrieve] |
5. | O'Connor, D., Moriarty, P., and Picciano, M. (1992) Int. J. Vitam. Nutr. Res. 62, 173-180[Medline] [Order article via Infotrieve] |
6. | Vitale, J., Streiff, R., and Hellerstein, E. (1965) Lancet ii, 393-394 |
7. | Thomas, E., and Amanna, K. (1997) FASEB J. 11, 396 |
8. | Milne, D., Johnson, L., Mahalko, J., and Sandstead, H. (1983) Am. J. Clin. Nutr. 37, 768-773[Abstract] |
9. | O'Connor, D., Picciano, M., Roos, M., and Easter, R. (1989) J. Nutr. 119, 1984-1991[Medline] [Order article via Infotrieve] |
10. | Hansen, H. (1964) On the Diagnosis of Folic Acid Deficiency , Almqvist & Wiksell, Stockholm, Sweden |
11. | Chanarin, I., Rothman, D., and Berry, V. (1965) Br. Med. J. 1, 480-485 |
12. | Roberts, P., St. John, D., Sinha, R., Stewart, J., Baird, I., Coghill, N., and Morgan, J. (1970) Br. J. Haematol. 20, 165-176 |
13. | Das, K., Herbert, V., Colman, N., and Longo, D. (1978) Br. J. Haematol. 39, 357-375[Medline] [Order article via Infotrieve] |
14. | Harrison, P., and Arosio, P. (1996) Biochim. Biophys. Acta 1275, 161-203[Medline] [Order article via Infotrieve] |
15. | Thomson, A., Rogers, J., and Leedman, P. (1999) Int. J. Biochem. Cell Biol. 31, 1139-1152[CrossRef][Medline] [Order article via Infotrieve] |
16. | Arosio, C., Fossati, L., Vigano, M., Trombini, P., Cazzaniga, G., and Poperno, A. (1999) Haematologica 84, 560-576[Medline] [Order article via Infotrieve] |
17. | Munro, H., and Linder, M. (1978) Physiol. Rev. 58, 318-387 |
18. |
Levi, S.,
Luzzago, A.,
Cesareni, G.,
Cozzi, A.,
Franceschinelli, F.,
Albertini, A.,
and Arosio, P.
(1988)
J. Biol. Chem.
263,
18086-18092 |
19. |
Picard, V.,
Renaudie, F.,
Porcher, C.,
Hentze, M.,
Grandchamp, B.,
and Beaumont, C.
(1996)
Blood
87,
2057-2064 |
20. |
Kwak, E.,
Larochelle, D.,
Beaumont, C.,
Torti, S.,
and Torti, F.
(1995)
J. Biol. Chem.
270,
15285-15293 |
21. | Wu, C., Habib, N., Mitry, R., Reitsma, P., van Deventer, S., and Chamuleau, R. (1997) Int. J. Oncol. 11, 187-192 |
22. | Holland, L., Wall, A., and Bhattacharya, A. (1991) Biochemistry 30, 1965-1972[Medline] [Order article via Infotrieve] |
23. |
Smirnov, I.,
Bailey, K.,
Flowers, C.,
Garrigues, N.,
and Wesselius, L.
(1999)
Am. J. Physiol.
277,
L257-L263 |
24. | Brady, M., Lilley, K., Treffry, A., Harrison, P., Hider, R., and Taylor, P. (1989) J. Inorg. Biochem. 35, 9-22[CrossRef][Medline] [Order article via Infotrieve] |
25. |
Oppenheim, E.,
Nasrallah, I.,
Mastri, M.,
and Stover, P.
(2000)
J. Biol. Chem.
275,
19268-19274 |
26. |
Appling, D.
(1991)
FASEB J.
5,
2645-2651 |
27. | Pfender, W., and Pizer, L. (1980) Arch. Biochem. Biophys. 200, 503-512[Medline] [Order article via Infotrieve] |
28. |
Girgis, S.,
Suh, J. R.,
Jolivet, J.,
and Stover, P. J.
(1997)
J. Biol. Chem.
272,
4729-4734 |
29. | Schirch, V., and Strong, W. (1989) Arch. Biochem. Biophys. 269, 371-380[Medline] [Order article via Infotrieve] |
30. |
Suh, J.,
Oppenheim, E.,
Gigis, S.,
and Stover, P.
(2000)
J. Biol. Chem.
275,
35646-35655 |
31. | Girgis, S., Nasrallah, I., Suh, J. R., Oppenheim, E., Zanetti, K., Mastri, M., and Stover, P. (1998) Gene (Amst.) 210, 315-324[CrossRef][Medline] [Order article via Infotrieve] |
32. | Liu, X., Reig, B., Nasrallah, I., and Stover, P. (2000) Biochemistry 39, 11523-11531[CrossRef][Medline] [Order article via Infotrieve] |
33. | Kalejta, R., and Hamlin, J. (1997) Exp. Cell Res. 231, 173-183[CrossRef][Medline] [Order article via Infotrieve] |
34. | Kulp, K., and Vulliet, P. (1996) Toxicol. Appl. Pharmacol. 139, 356-364[CrossRef][Medline] [Order article via Infotrieve] |
35. |
Picard, V.,
Epsztejn, S.,
Santambrogio, P.,
Cabantchik, Z.,
and Beaumont, C.
(1998)
J. Biol. Chem.
273,
15382-15386 |
36. | Ponka, P. (1999) Kidney Int. 55, S2-S11[CrossRef] |
37. | Chu, E., and Allegra, C. (1996) Bioessays 18, 191-198[Medline] [Order article via Infotrieve] |
38. | Chu, E., Takimoto, C., Voeller, D., Grem, J., and Allegra, C. (1993) Biochemistry 32, 4756-4760[Medline] [Order article via Infotrieve] |
39. | Chu, E., Voeller, D., Koeller, K., Drake, J., Takimot, C., Maley, G., Maley, F., and Allegra, C. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 517-521[Abstract] |
40. | Jansen, M., de Moor, C., Sussenbach, J., and van den Brande, J. (1995) Pediatr. Res. 37, 681-686[Abstract] |
41. |
Allen, R.,
Stabler, S.,
Savage, D.,
and Lindenbaum, J.
(1993)
FASEB J.
7,
1344-1353 |
42. |
Heise, T.,
Nath, A.,
Jungermann, K.,
and Christ, B.
(1997)
J. Biol. Chem.
272,
20222-20292 |
43. |
Blount, B.,
Mack, M.,
Wher, C.,
MacGregor, J.,
Hiatt, R.,
Wang, G.,
Wickeramsinghe, S.,
Everson, R.,
and Ames, B.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
3290-3295 |
44. | Melynk, S., Pogribna, M., Miller, B., Basnakian, A., Pogribny, I., and James, S. (1999) Cancer Lett. 146, 35-44[CrossRef][Medline] [Order article via Infotrieve] |
45. | Kim, Y. (1999) J. Nutr. Biochem. 10, 66-68[CrossRef] |
46. |
Fleming, A.,
and Copp, A.
(1998)
Science
280,
2107-2109 |
47. | Nakshatri, H., Bouillet, P., Bhat-Naksharti, P., and Chambon, P. (1997) Gene (Amst.) 174, 79-84[CrossRef] |
48. | Zhu, L., Bagchi, M., and Bagchi, I. (1995) Endocrinology 136, 4106-4115[Abstract] |
49. |
Wu, K.,
Polack, A.,
and Dalla-Favera, R.
(1999)
Science
283,
676-679 |
50. |
Leggett, B.,
Brown, N.,
Bryant, S.,
Duplock, L.,
Powell, L.,
and Halliday, J.
(1990)
Clin. Chem.
36,
1350-1355 |
51. | McNulty, H., McPartlin, J., Weir, D., and Scott, J. (1993) J. Nutr. 123, 1089-1093[Medline] [Order article via Infotrieve] |
52. | Gruner, B., and Weitman, S. (1999) Invest. New Drugs 16, 205-219[CrossRef] |
53. | Eichner, E., and Hillman, R. (1973) J. Clin. Invest. 52, 584-591[Medline] [Order article via Infotrieve] |